JP2006507329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507329A5 JP2006507329A5 JP2004552424A JP2004552424A JP2006507329A5 JP 2006507329 A5 JP2006507329 A5 JP 2006507329A5 JP 2004552424 A JP2004552424 A JP 2004552424A JP 2004552424 A JP2004552424 A JP 2004552424A JP 2006507329 A5 JP2006507329 A5 JP 2006507329A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- halo
- phenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001257 hydrogen Substances 0.000 claims 64
- 229910052739 hydrogen Inorganic materials 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 125000001475 halogen functional group Chemical group 0.000 claims 51
- 150000002431 hydrogen Chemical class 0.000 claims 49
- 125000001188 haloalkyl group Chemical group 0.000 claims 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims 39
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- -1 nitro, cyano, phenyl Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000004043 oxo group Chemical group O=* 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 206010010904 Convulsion Diseases 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- DRPORMUHNHGFLD-UHFFFAOYSA-N 4-chloro-2-[(2-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1I DRPORMUHNHGFLD-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000005809 status epilepticus Diseases 0.000 claims 2
- BIAYVBTUMYRJBI-UHFFFAOYSA-N 1-(3-bromophenyl)-3-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]urea Chemical compound C=1C=CC(Br)=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 BIAYVBTUMYRJBI-UHFFFAOYSA-N 0.000 claims 1
- JIMXLVJAMRAHOZ-UHFFFAOYSA-N 1-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 JIMXLVJAMRAHOZ-UHFFFAOYSA-N 0.000 claims 1
- JHUBTWRPSAEQAH-UHFFFAOYSA-N 1-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC=2C(=CC=C(Cl)C=2)C=2NC(=O)ON=2)=C1 JHUBTWRPSAEQAH-UHFFFAOYSA-N 0.000 claims 1
- VMKDUMUALKECDD-UHFFFAOYSA-N 1-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 VMKDUMUALKECDD-UHFFFAOYSA-N 0.000 claims 1
- JRTRHAJORIWUJX-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylcarbamoylamino)-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(OCO2)C2=C1 JRTRHAJORIWUJX-UHFFFAOYSA-N 0.000 claims 1
- SWXCGNGGTRXUTL-UHFFFAOYSA-N 2-[(2-bromophenyl)carbamoylamino]-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1Br SWXCGNGGTRXUTL-UHFFFAOYSA-N 0.000 claims 1
- JHBDMFCBQQGZTP-UHFFFAOYSA-N 2-[(3-bromophenyl)carbamoylamino]-4-chloro-5-methylbenzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=CC(Br)=C1 JHBDMFCBQQGZTP-UHFFFAOYSA-N 0.000 claims 1
- FUZOGGHSNBXLIL-UHFFFAOYSA-N 2-[(3-bromophenyl)carbamoylamino]-4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Br)=C1 FUZOGGHSNBXLIL-UHFFFAOYSA-N 0.000 claims 1
- LBWDNZCDWOZSOL-UHFFFAOYSA-N 2-[2-[(3-bromophenyl)carbamoylamino]-4-chlorophenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Br)=C1 LBWDNZCDWOZSOL-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- XNDJMNYMZWBAKT-UHFFFAOYSA-N 4-chloro-2-(1h-indol-2-ylcarbamoylamino)-5-methylbenzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC2=CC=CC=C2N1 XNDJMNYMZWBAKT-UHFFFAOYSA-N 0.000 claims 1
- PQNJQLMZJYDJCS-UHFFFAOYSA-N 4-chloro-2-(1h-indol-2-ylcarbamoylamino)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC2=CC=CC=C2N1 PQNJQLMZJYDJCS-UHFFFAOYSA-N 0.000 claims 1
- ODWUYZAAMNLBKT-UHFFFAOYSA-N 4-chloro-2-(naphthalen-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C=CC=C2)C2=C1 ODWUYZAAMNLBKT-UHFFFAOYSA-N 0.000 claims 1
- KWZAOORTSIYEAN-UHFFFAOYSA-N 4-chloro-2-(phenylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1 KWZAOORTSIYEAN-UHFFFAOYSA-N 0.000 claims 1
- LYJNLSVTXUEARX-UHFFFAOYSA-N 4-chloro-2-(pyridin-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=N1 LYJNLSVTXUEARX-UHFFFAOYSA-N 0.000 claims 1
- NLJJXBBIDCIREM-UHFFFAOYSA-N 4-chloro-2-(thiophen-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CS1 NLJJXBBIDCIREM-UHFFFAOYSA-N 0.000 claims 1
- IVTCCQWGKNDDCB-UHFFFAOYSA-N 4-chloro-2-[(2-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1O IVTCCQWGKNDDCB-UHFFFAOYSA-N 0.000 claims 1
- VSZKUIZXGWUDLH-UHFFFAOYSA-N 4-chloro-2-[(2-methoxyphenyl)carbamoylamino]benzoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC1=CC(Cl)=CC=C1C(O)=O VSZKUIZXGWUDLH-UHFFFAOYSA-N 0.000 claims 1
- DCLLIIGZJAINFF-UHFFFAOYSA-N 4-chloro-2-[(2-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1C1=CC=CC=C1 DCLLIIGZJAINFF-UHFFFAOYSA-N 0.000 claims 1
- PYDGXNVMBSNMMZ-UHFFFAOYSA-N 4-chloro-2-[(3-chlorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Cl)=C1 PYDGXNVMBSNMMZ-UHFFFAOYSA-N 0.000 claims 1
- YJXCIVXLYIAFFB-UHFFFAOYSA-N 4-chloro-2-[(3-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(O)=C1 YJXCIVXLYIAFFB-UHFFFAOYSA-N 0.000 claims 1
- HDVLBTNZJJUZTI-UHFFFAOYSA-N 4-chloro-2-[(3-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(I)=C1 HDVLBTNZJJUZTI-UHFFFAOYSA-N 0.000 claims 1
- YYTGSSNODJDIJV-UHFFFAOYSA-N 4-chloro-2-[(3-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C=2C=CC=CC=2)=C1 YYTGSSNODJDIJV-UHFFFAOYSA-N 0.000 claims 1
- MLGALOZSVFKMSG-UHFFFAOYSA-N 4-chloro-2-[(4-chlorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(Cl)C=C1 MLGALOZSVFKMSG-UHFFFAOYSA-N 0.000 claims 1
- FWQMESGSECYCCQ-UHFFFAOYSA-N 4-chloro-2-[(4-fluorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(F)C=C1 FWQMESGSECYCCQ-UHFFFAOYSA-N 0.000 claims 1
- QLLLLTXSZLAPFG-UHFFFAOYSA-N 4-chloro-2-[(4-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(O)C=C1 QLLLLTXSZLAPFG-UHFFFAOYSA-N 0.000 claims 1
- RGDBBRGPGZALER-UHFFFAOYSA-N 4-chloro-2-[(4-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(I)C=C1 RGDBBRGPGZALER-UHFFFAOYSA-N 0.000 claims 1
- IGVRXEWRIRSEMV-UHFFFAOYSA-N 4-chloro-2-[(4-methoxyphenyl)carbamoylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1=CC(Cl)=CC=C1C(O)=O IGVRXEWRIRSEMV-UHFFFAOYSA-N 0.000 claims 1
- MHKORSIIJIQRMD-UHFFFAOYSA-N 4-chloro-2-[(4-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 MHKORSIIJIQRMD-UHFFFAOYSA-N 0.000 claims 1
- PBNRVTPDAJAJOD-UHFFFAOYSA-N 4-chloro-2-[(9-oxofluoren-3-yl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C(=O)C=2C3=CC=CC=2)C3=C1 PBNRVTPDAJAJOD-UHFFFAOYSA-N 0.000 claims 1
- PHAGATSOEHSZNZ-UHFFFAOYSA-N 4-chloro-2-[[2-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1C(F)(F)F PHAGATSOEHSZNZ-UHFFFAOYSA-N 0.000 claims 1
- KBKIYZZQLOFTDK-UHFFFAOYSA-N 4-chloro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 KBKIYZZQLOFTDK-UHFFFAOYSA-N 0.000 claims 1
- GNCZTZCPXFDPLI-UHFFFAOYSA-N 4-chloro-2-[[oxo-[3-(trifluoromethyl)anilino]methyl]amino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 GNCZTZCPXFDPLI-UHFFFAOYSA-N 0.000 claims 1
- UAJJKABSBNCYAN-UHFFFAOYSA-N 4-chloro-5-methyl-2-(naphthalen-2-ylcarbamoylamino)benzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=C(C=CC=C2)C2=C1 UAJJKABSBNCYAN-UHFFFAOYSA-N 0.000 claims 1
- LLLKNTGMZQZAIH-UHFFFAOYSA-N 4-chloro-5-methyl-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 LLLKNTGMZQZAIH-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- YJLYKRYWHIFVSR-UHFFFAOYSA-N 6-chloro-n-naphthalen-2-yl-3-oxo-2h-indazole-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2C(O)=NN1C(=O)NC1=CC=C(C=CC=C2)C2=C1 YJLYKRYWHIFVSR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000002381 Brain Hypoxia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010051290 Central nervous system lesion Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013647 Drowning Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 108010009117 Gluk1 kainate receptor Proteins 0.000 claims 1
- 206010019005 Haemorrhagic cerebral infarction Diseases 0.000 claims 1
- 208000027109 Headache disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010038669 Respiratory arrest Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical class 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003179 convulsant agent Substances 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000002461 excitatory amino acid Effects 0.000 claims 1
- 239000003257 excitatory amino acid Substances 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- XQJXNILPLUCHQG-UHFFFAOYSA-N n-phenyl-1h-indazole-3-carboxamide Chemical class N=1NC2=CC=CC=C2C=1C(=O)NC1=CC=CC=C1 XQJXNILPLUCHQG-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
- RDBWPJMZIPZQKR-UHFFFAOYSA-N CC1=NN(C)NN1 Chemical compound CC1=NN(C)NN1 RDBWPJMZIPZQKR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201803 | 2002-11-21 | ||
| PCT/DK2003/000768 WO2004046090A2 (en) | 2002-11-21 | 2003-11-10 | Aryl ureido derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507329A JP2006507329A (ja) | 2006-03-02 |
| JP2006507329A5 true JP2006507329A5 (cg-RX-API-DMAC7.html) | 2007-01-25 |
Family
ID=32319497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552424A Pending JP2006507329A (ja) | 2002-11-21 | 2003-11-10 | 新規アリールウレイド安息香酸誘導体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7521480B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1565429B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006507329A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1714076A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE431335T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003280308A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2502705A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60327652D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2327834T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05005409A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ539499A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1565429E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004046090A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US20070249670A1 (en) * | 2004-11-09 | 2007-10-25 | Smithkline Beecham Corporation | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof |
| FR2878522B1 (fr) * | 2004-12-01 | 2008-04-18 | Merck Sante Soc Par Actions Si | Nouveaux inhibiteurs specifiques de la caspas-10 |
| JP2008524158A (ja) * | 2004-12-17 | 2008-07-10 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル活性化剤として有用なジフェニル尿素誘導体 |
| ATE499370T1 (de) | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
| US7728008B2 (en) | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7816382B2 (en) | 2005-06-27 | 2010-10-19 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition |
| WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ES2352796T3 (es) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas. |
| AU2006302174B2 (en) * | 2005-10-06 | 2013-06-20 | Exelixis, Inc. | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 |
| KR20080103106A (ko) | 2006-03-14 | 2008-11-26 | 뉴로서치 에이/에스 | 디페닐우레아 유도체 및 클로라이드 채널 차단제 또는 ＢＫＣａ 채널 조정자로서의 이의 용도 |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE102007012908A1 (de) | 2007-03-19 | 2008-09-25 | Momentive Performance Materials Gmbh | Neue Polyamid-Polysiloxan-Verbindungen |
| AU2008309003A1 (en) * | 2007-09-28 | 2009-04-09 | Glaxosmithkline Llc | Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| WO2009068557A1 (en) * | 2007-11-28 | 2009-06-04 | Neurosearch A/S | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
| EP2493468A1 (en) * | 2009-10-30 | 2012-09-05 | Sanofi | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
| WO2016127085A1 (en) | 2015-02-07 | 2016-08-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | hTRPV1 CHEMICAL AGENTS |
| US10647665B2 (en) | 2016-06-22 | 2020-05-12 | Fudan University | Biaryl urea derivative or salt thereof and preparation process and use for the same |
| CN106008371A (zh) * | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN106946786A (zh) * | 2017-04-11 | 2017-07-14 | 白银澐新生物科技有限公司 | 一种1‑苄基‑3‑羟基‑1h‑3‑吲唑钠盐的制备方法 |
| CN111116420B (zh) * | 2019-12-31 | 2022-01-14 | 浙江工业大学 | 一种对称脲类化合物的制备方法 |
| CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH220682A (de) * | 1940-02-05 | 1942-04-30 | Geigy Ag J R | Verfahren zum Schützen von Pelzen, Federn, Haaren, fibrösen Materialien und andern Waren gegen Schädlinge. |
| US2722544A (en) * | 1950-12-26 | 1955-11-01 | Variapat Ag | Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation |
| GB709455A (en) * | 1950-12-26 | 1954-05-26 | Variapat Ag | Water-soluble asymmetric ureas and thioureas and a process for their production |
| GB828231A (en) * | 1955-10-20 | 1960-02-17 | Geigy Ag J R | Improvements relating to insecticidal compounds and their use |
| GB1055786A (en) * | 1963-07-12 | 1967-01-18 | Ici Ltd | Urea derivatives |
| US3332981A (en) * | 1964-09-14 | 1967-07-25 | Gen Aniline & Film Corp | Urea stilbene brighteners |
| GB1210596A (en) * | 1967-04-06 | 1970-10-28 | Armour Grocery Products Compan | Antiseptic compositions |
| JPS5936614B2 (ja) * | 1973-03-09 | 1984-09-05 | フアイザ− インコ−ポレ−テツド | 安息香酸誘導体およびそれらの塩の製造方法 |
| DE2315302A1 (de) * | 1973-03-27 | 1974-10-17 | Bayer Ag | Verfahren zur herstellung von nitrochinazolindionen |
| DE2928485A1 (de) * | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| GB8429739D0 (en) * | 1984-11-24 | 1985-01-03 | Fbc Ltd | Fungicides |
| GB8820129D0 (en) * | 1988-08-24 | 1988-09-28 | Schering Agrochemicals Ltd | Fungicides |
| DK41193D0 (da) | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| EP0693386B1 (en) * | 1994-07-21 | 1997-02-05 | Nippon Paper Industries Co., Ltd. | Aminobenzenesulfonamide derivatives as colour-developers for thermosensitive recording materials |
| CA2161376C (en) * | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
| WO1996025157A1 (en) * | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| US5985872A (en) * | 1995-05-24 | 1999-11-16 | G.D. Searle & Co. | 2-amino-benzoxazinones for the treatment of viral infections |
| US5811369A (en) * | 1995-12-01 | 1998-09-22 | Nippon Paper Industries Co., Ltd. | Thermal recording medium |
| DE69612358T2 (de) * | 1995-12-08 | 2001-07-12 | Nippon Paper Industries Co. Ltd., Tokio/Tokyo | Wärmeempfindliches Aufzeichnungsmedium |
| US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| JP4073489B2 (ja) * | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 |
| AU2962297A (en) | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| NZ337976A (en) | 1997-04-22 | 2001-05-25 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
| US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| WO1999038846A1 (en) | 1998-01-30 | 1999-08-05 | Procept, Inc. | Immunosuppressive agents |
| NZ510098A (en) | 1998-10-22 | 2003-09-26 | Neurosearch As | Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel |
| SE9903894D0 (sv) * | 1999-10-28 | 1999-10-28 | New Pharma Research Ab | Novel compounds |
| AU2002223492A1 (en) * | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| WO2002064128A1 (en) | 2001-02-15 | 2002-08-22 | Neurosearch A/S | Treatment of diseases characterized by excessive or insufficient cell death |
| WO2002070467A1 (en) | 2001-02-26 | 2002-09-12 | 4Sc Ag | Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments |
| WO2003000245A1 (en) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| DE10131133A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Pyridazinone |
| EP1427412A1 (en) | 2001-09-13 | 2004-06-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating cytokine mediated diseases |
-
2003
- 2003-11-10 AU AU2003280308A patent/AU2003280308A1/en not_active Abandoned
- 2003-11-10 JP JP2004552424A patent/JP2006507329A/ja active Pending
- 2003-11-10 ES ES03770917T patent/ES2327834T3/es not_active Expired - Lifetime
- 2003-11-10 CA CA002502705A patent/CA2502705A1/en not_active Abandoned
- 2003-11-10 EP EP03770917A patent/EP1565429B1/en not_active Expired - Lifetime
- 2003-11-10 CN CNA200380103761XA patent/CN1714076A/zh active Pending
- 2003-11-10 AT AT03770917T patent/ATE431335T1/de not_active IP Right Cessation
- 2003-11-10 US US10/535,683 patent/US7521480B2/en not_active Expired - Fee Related
- 2003-11-10 DE DE60327652T patent/DE60327652D1/de not_active Expired - Lifetime
- 2003-11-10 NZ NZ539499A patent/NZ539499A/en unknown
- 2003-11-10 PT PT03770917T patent/PT1565429E/pt unknown
- 2003-11-10 MX MXPA05005409A patent/MXPA05005409A/es unknown
- 2003-11-10 WO PCT/DK2003/000768 patent/WO2004046090A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507329A5 (cg-RX-API-DMAC7.html) | ||
| JP2020055824A (ja) | 中枢神経系疾患および障害の治療に有効な新規化合物 | |
| TW555735B (en) | Diarylpropylamines, methods for their preparation and pharmaceutical compositions containing them | |
| US20120225845A1 (en) | Compounds for diseases and disorders | |
| US20170313719A1 (en) | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto | |
| JP5342451B2 (ja) | Ｐｄｅ４阻害剤として有用な置換アセトフェノン | |
| JP5717031B2 (ja) | 置換されたアゾール誘導体、この誘導体を含む医薬組成物、及びこれを利用したパーキンソン病の治療方法 | |
| JP2011528372A (ja) | α７ニコチン性アセチルコリンレセプターインヒビター | |
| FI78691B (fi) | Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. | |
| JP2006022108A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526082A5 (cg-RX-API-DMAC7.html) | ||
| JP2006507329A (ja) | 新規アリールウレイド安息香酸誘導体及びその使用 | |
| BRPI0806665A2 (pt) | compostos moduladores de receptores de acetilcolina nicotìnicos, composição farmacêutica e uso dos mesmos | |
| CN106536498A (zh) | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 | |
| EP2468732B1 (en) | 1H-Quinazoline-2,4-diones | |
| US20080249135A1 (en) | Compounds for alzheimer's disease | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| RU2655919C2 (ru) | Производные аминоциклобутана, способ их получения и их применение в качестве лекарственных средств | |
| JP2010505867A (ja) | ピラゾール化合物 | |
| JP2008508247A5 (cg-RX-API-DMAC7.html) | ||
| JP2004501136A (ja) | Ｎｍｄａ受容体の選択的拮抗薬としてのアミジン誘導体 | |
| JP2006503062A5 (cg-RX-API-DMAC7.html) | ||
| JP2008542365A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529813A (ja) | チアジアジン誘導体 | |
| JPH02131452A (ja) | 抗痙攣用または神経保護用医薬 |